NCT03245736View on ClinicalTrials.gov

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

January 10, 2019

Study Completion Date

January 10, 2019

Conditions
Ovary CancerCervix CancerEndometrium CancerBladder CancerProstate CancerEsophagus CancerLung Cancer, Nonsmall CellSquamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Tisotumab Vedotin

All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).

Trial Locations (4)

33136

Brian Slomovitz, Miami

SM2 5PT

Johann de Bono, Chelsea

Unknown

Beatson Cancer Centre, Glasgow

M20 4BX

Fiona Thistlethwaite, Manchester

Sponsors

Collaborators (1)

Genmab
All Listed Sponsors
collaborator

Genmab

INDUSTRY

lead

Seagen Inc.

INDUSTRY

NCT03245736 - Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | Biotech Hunter | Biotech Hunter